1. Home
  2. TNXP vs BGSF Comparison

TNXP vs BGSF Comparison

Compare TNXP & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • BGSF
  • Stock Information
  • Founded
  • TNXP 2007
  • BGSF 2007
  • Country
  • TNXP United States
  • BGSF United States
  • Employees
  • TNXP N/A
  • BGSF N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • BGSF Professional Services
  • Sector
  • TNXP Health Care
  • BGSF Consumer Discretionary
  • Exchange
  • TNXP Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • TNXP 71.6M
  • BGSF 66.0M
  • IPO Year
  • TNXP N/A
  • BGSF N/A
  • Fundamental
  • Price
  • TNXP $0.38
  • BGSF $5.28
  • Analyst Decision
  • TNXP Strong Buy
  • BGSF
  • Analyst Count
  • TNXP 2
  • BGSF 0
  • Target Price
  • TNXP $53.50
  • BGSF N/A
  • AVG Volume (30 Days)
  • TNXP 102.7M
  • BGSF 18.8K
  • Earning Date
  • TNXP 11-12-2024
  • BGSF 03-12-2025
  • Dividend Yield
  • TNXP N/A
  • BGSF 2.85%
  • EPS Growth
  • TNXP N/A
  • BGSF N/A
  • EPS
  • TNXP N/A
  • BGSF N/A
  • Revenue
  • TNXP $11,291,000.00
  • BGSF $281,656,000.00
  • Revenue This Year
  • TNXP $64.71
  • BGSF N/A
  • Revenue Next Year
  • TNXP $24.49
  • BGSF $5.63
  • P/E Ratio
  • TNXP N/A
  • BGSF N/A
  • Revenue Growth
  • TNXP 183.05
  • BGSF N/A
  • 52 Week Low
  • TNXP $0.12
  • BGSF $5.03
  • 52 Week High
  • TNXP $12.48
  • BGSF $10.50
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 55.72
  • BGSF 43.79
  • Support Level
  • TNXP $0.37
  • BGSF $5.03
  • Resistance Level
  • TNXP $0.58
  • BGSF $5.37
  • Average True Range (ATR)
  • TNXP 0.07
  • BGSF 0.22
  • MACD
  • TNXP 0.01
  • BGSF 0.03
  • Stochastic Oscillator
  • TNXP 43.06
  • BGSF 48.08

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About BGSF BGSF Inc.

BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.

Share on Social Networks: